Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) says that the European Commission has granted marketing authorization for Cinqaero (reslizumab) in the 28 countries of the European Union in addition to Norway, Liechtenstein and Iceland.
Cinqaero is a humanized interleukin-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
The approval follows a positive recommendation in June from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in June. Cinqaero is the second humanized interleukin-5 (IL-5) inhibitor to be approved in the EU, with GlaxoSmithKline's potential blockbuster Nucala (mepolizumab) already available on the market. Analysts on average expect Nucala to generate annual sales of $756 million by 2020. However, some believe it has the potential for sales of $1 billion-plus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze